NOVARTIS AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 92.32 CHF | +1.97% |
|
+4.94% | +8.78% |
| May. 10 | Novartis’ Scemblix Gets Third US FDA Breakthrough Therapy Designation | MT |
| May. 10 | Novartis Gets FDA Breakthrough Therapy Designation for Scemblix | DJ |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Sector Other Pharmaceuticals
| Capi. | Sales growth | Profitability | Finances | EV / Sales | P/E ratio | |
|---|---|---|---|---|---|---|
| 208B | ||||||
| 684B | ||||||
| 568B | ||||||
| 361B | ||||||
| 329B | ||||||
| 284B |
- Stock Market
- Equities
- NOVN Stock
- Charts Novartis AG
- Sector Chart
